A Medical Device Daily
Echo Therapeutics (Franklin, Massachusetts) reported the issuance of U.S. patent No. 7,432,069 covering compositions and methods for the preparation of a polyethylene glycol (PEG)-based hydrogel as a key component of its Symphony Transdermal Continuous Glucose Monitoring (tCGM) System.
"Our PEG hydrogel, specifically designed to enable transdermal biosensing, is characterized by excellent stability, sensitivity, integrity and biocompatibility, making our Symphony tCGM System a desirable system for non-invasive continuous glucose monitoring," said Chairman/CEO Patrick Mooney, MD. "This patent is critical to our intellectual property strategy for protecting our leading position in non-invasive, tCGM markets worldwide."